Phase III Data Support Chemo-Free Approach to ALL.
In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy-imatinib regimen for patients with
APA
(2026). Phase III Data Support Chemo-Free Approach to ALL.. Cancer discovery, 16(1), OF1. https://doi.org/10.1158/2159-8290.CD-NW2025-0110
MLA
. "Phase III Data Support Chemo-Free Approach to ALL.." Cancer discovery, vol. 16, no. 1, 2026, pp. OF1.
PMID
41405203
Abstract
In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy-imatinib regimen for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings could change the standard of care for the disease.
MeSH Terms
Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Imidazoles; Clinical Trials, Phase III as Topic; Antibodies, Bispecific; Pyridazines; Antineoplastic Combined Chemotherapy Protocols; Imatinib Mesylate